Omeros Signs Major Deal with Novo Nordisk

Omeros ( (OMER) ) has issued an update.

On October 10, 2025, Omeros Corporation entered into an Asset Purchase and License Agreement with Novo Nordisk, granting Novo Nordisk exclusive global rights to develop and commercialize zaltenibart (OMS906), Omeros’ lead human monoclonal antibody targeting MASP-3. The agreement could bring Omeros up to $2.1 billion in payments, including an upfront payment of $240 million, and tiered royalties on net sales. This transaction is expected to close in the fourth quarter of 2025 and will enable Novo Nordisk to enhance its Rare Disease portfolio, while Omeros retains rights to its preclinical MASP-3 programs unrelated to zaltenibart.

The most recent analyst rating on (OMER) stock is a Buy with a $5.40 price target. To see the full list of analyst forecasts on Omeros stock, see the OMER Stock Forecast page.

Spark’s Take on OMER Stock

According to Spark, TipRanks’ AI Analyst, OMER is a Underperform.

Omeros faces significant financial instability with no revenue and high debt, which heavily impacts its score. Technical indicators suggest some potential for short-term recovery, but poor valuation and ongoing losses are concerning. The company’s strategic focus on drug development and partnerships offers some optimism, but financial recovery is crucial for improvement.

To see Spark’s full report on OMER stock, click here.

More about Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is under regulatory review for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Average Trading Volume: 1,117,291

Technical Sentiment Signal: Sell

Current Market Cap: $285.2M

For detailed information about OMER stock, go to TipRanks’ Stock Analysis page.